Arcus Biosciences, Inc. (RCUS) Form 424B5 — Oct 21, 2026
Arcus Biosciences filed a preliminary prospectus supplement (424B5) on October 21, 2026 for an underwritten follow-on offering of common stock off its February 2026 shelf, with Jefferies, Leerink Partners and TD Cowen as book-runners. Share count, price, and expected proceeds are left blank pending pricing; the last reported sale price was $23.75 on October 20, 2026. The offering came one day after Arcus presented new ARC-20 data for casdatifan in clear cell renal cell carcinoma, including 86% and 69% six- and 12-month landmark PFS for first-line casdatifan plus zimberelimab (n=30) and median PFS of 14.5 months for second-line casdatifan plus cabozantinib.
Key figures
- Cash Position
- 694000000
- Shares Outstanding
- 127018631
- Lockup days
- 60
- Underwriters
- Jefferies, Leerink Partners, TD Cowen
- Options outstanding
- 17,395,615 at weighted-average exercise price of $20.19
- Net tangible book value
- $463.2 million
- Preliminary cash estimate
- $694.0 million as of September 30, 2026 (unaudited)
- Last sale price oct 20 2026
- $23.75 per share
- Net tangible book value per share
- $3.65
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.